Literature DB >> 17872377

Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor.

Thomas Dean1, Jean-Pierre Vilardaga, John T Potts, Thomas J Gardella.   

Abstract

PTH and PTHrP use the same G protein-coupled receptor, the PTH/PTHrP receptor (PTHR), to mediate their distinct biological actions. The extent to which the mechanisms by which the two ligands bind to the PTHR differ is unclear. We examined this question using several pharmacological and biophysical approaches. Kinetic dissociation and equilibrium binding assays revealed that the binding of [(125)I]PTHrP(1-36) to the PTHR was more sensitive to GTPgammaS (added to functionally uncouple PTHR-G protein complexes) than was the binding of [(125)I]PTH(1-34) ( approximately 75% maximal inhibition vs. approximately 20%). Fluorescence resonance energy transfer-based kinetic analyses revealed that PTHrP(1-36) bound to the PTHR more slowly and dissociated from it more rapidly than did PTH(1-34). The cAMP signaling response capacity of PTHrP(1-36) in cells decayed more rapidly than did that of PTH(1-34) (t(1/2) = approximately 1 vs. approximately 2 h). Divergent residue 5 in the ligand, Ile in PTH and His in PTHrP, was identified as a key determinant of the altered receptor-interaction responses exhibited by the two peptides. We conclude that whereas PTH and PTHrP bind similarly to the G protein-coupled PTHR conformation (RG), PTH has a greater capacity to bind to the G protein-uncoupled conformation (R(0)) and, hence, can produce cumulatively greater signaling responses (via R(0)-->RG isomerization) than can PTHrP. Such conformational selectivity may relate to the distinct modes by which PTH and PTHrP act biologically, endocrine vs. paracrine, and may help explain reported differences in the effects that the ligands have on calcium and bone metabolism when administered to humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17872377      PMCID: PMC2194631          DOI: 10.1210/me.2007-0274

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  39 in total

1.  Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study.

Authors:  Mara J Horwitz; Mary Beth Tedesco; Susan M Sereika; Adolfo Garcia-Ocaña; Alessandro Bisello; Bruce W Hollis; Caren Gundberg; Andrew F Stewart
Journal:  Osteoporos Int       Date:  2005-09-07       Impact factor: 4.507

2.  Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism.

Authors:  Marián Castro; Viacheslav O Nikolaev; Dieter Palm; Martin J Lohse; Jean-Pierre Vilardaga
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-18       Impact factor: 11.205

Review 3.  Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis.

Authors:  Armen H Tashjian; Robert F Gagel
Journal:  J Bone Miner Res       Date:  2005-11-11       Impact factor: 6.741

Review 4.  PTHrP and skeletal development.

Authors:  Henry M Kronenberg
Journal:  Ann N Y Acad Sci       Date:  2006-04       Impact factor: 5.691

5.  Osteoblast-derived PTHrP is a physiological regulator of bone formation.

Authors:  T John Martin
Journal:  J Clin Invest       Date:  2005-09       Impact factor: 14.808

6.  Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34.

Authors:  Dengshun Miao; Bin He; Yebin Jiang; Tatsuya Kobayashi; Maria A Sorocéanu; Jenny Zhao; Hanyi Su; Xinkang Tong; Norio Amizuka; Ajay Gupta; Harry K Genant; Henry M Kronenberg; David Goltzman; Andrew C Karaplis
Journal:  J Clin Invest       Date:  2005-09       Impact factor: 14.808

7.  Initial characterization of PTH-related protein gene-driven lacZ expression in the mouse.

Authors:  Xuesong Chen; Carolyn M Macica; Barbara E Dreyer; Vicki E Hammond; Julie R Hens; William M Philbrick; Arthur E Broadus
Journal:  J Bone Miner Res       Date:  2005-10-10       Impact factor: 6.741

8.  Mechanisms of ligand binding to the parathyroid hormone (PTH)/PTH-related protein receptor: selectivity of a modified PTH(1-15) radioligand for GalphaS-coupled receptor conformations.

Authors:  Thomas Dean; Agnes Linglart; Matthew J Mahon; Murat Bastepe; Harald Jüppner; John T Potts; Thomas J Gardella
Journal:  Mol Endocrinol       Date:  2005-12-08

9.  Role of amino acid side chains in region 17-31 of parathyroid hormone (PTH) in binding to the PTH receptor.

Authors:  Thomas Dean; Ashok Khatri; Zhanna Potetinova; Gordon E Willick; Thomas J Gardella
Journal:  J Biol Chem       Date:  2006-08-21       Impact factor: 5.157

10.  The mid-region of parathyroid hormone (1-34) serves as a functional docking domain in receptor activation.

Authors:  Angela Wittelsberger; Martina Corich; Beena E Thomas; Byung-Kwon Lee; Alessandra Barazza; Paul Czodrowski; Dale F Mierke; Michael Chorev; Michael Rosenblatt
Journal:  Biochemistry       Date:  2006-02-21       Impact factor: 3.162

View more
  74 in total

Review 1.  Current Status of Bone-Forming Therapies for the Management of Osteoporosis.

Authors:  Anne Sophie Koldkjær Sølling; Torben Harsløf; Bente Langdahl
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

2.  Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation.

Authors:  Makoto Okazaki; Sebastien Ferrandon; Jean-Pierre Vilardaga; Mary L Bouxsein; John T Potts; Thomas J Gardella
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-22       Impact factor: 11.205

3.  Time-resolved fluorescence ligand binding for G protein-coupled receptors.

Authors:  Alexander Emami-Nemini; Thomas Roux; Marion Leblay; Emmanuel Bourrier; Laurent Lamarque; Eric Trinquet; Martin J Lohse
Journal:  Nat Protoc       Date:  2013-06-13       Impact factor: 13.491

Review 4.  Osteoanabolic and dual action drugs.

Authors:  Gaia Tabacco; John P Bilezikian
Journal:  Br J Clin Pharmacol       Date:  2019-04-03       Impact factor: 4.335

5.  Acute down-regulation of sodium-dependent phosphate transporter NPT2a involves predominantly the cAMP/PKA pathway as revealed by signaling-selective parathyroid hormone analogs.

Authors:  So Nagai; Makoto Okazaki; Hiroko Segawa; Clemens Bergwitz; Thomas Dean; John T Potts; Matthew J Mahon; Thomas J Gardella; Harald Jüppner
Journal:  J Biol Chem       Date:  2010-11-03       Impact factor: 5.157

6.  A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover.

Authors:  Mara J Horwitz; Mary Beth Tedesco; Susan M Sereika; Linda Prebehala; Caren M Gundberg; Bruce W Hollis; Alessandro Bisello; Adolfo Garcia-Ocaña; Raquel M Carneiro; Andrew F Stewart
Journal:  J Bone Miner Res       Date:  2011-09       Impact factor: 6.741

Review 7.  Regulation of Skeletal Homeostasis.

Authors:  Mone Zaidi; Tony Yuen; Li Sun; Clifford J Rosen
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

Review 8.  Perspective: Implications of Ligand-Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors.

Authors:  Wijnand J C van der Velden; Laura H Heitman; Mette M Rosenkilde
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-18

9.  Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH.

Authors:  Akira Maeda; Makoto Okazaki; David M Baron; Thomas Dean; Ashok Khatri; Mathew Mahon; Hiroko Segawa; Abdul B Abou-Samra; Harald Jüppner; Kenneth D Bloch; John T Potts; Thomas J Gardella
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

10.  Picomolar Affinity Antagonist and Sustained Signaling Agonist Peptide Ligands for the Adrenomedullin and Calcitonin Gene-Related Peptide Receptors.

Authors:  Jason M Booe; Margaret L Warner; Augen A Pioszak
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.